Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

96
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
96
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

600
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
600
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

29
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
29
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

622
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
622
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.

Clinical pharmacokinetics·2026
Same author

Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Exposure-Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Population Pharmacokinetics of Atogepant for the Prevention of Migraine.

Clinical pharmacokinetics·2025
Same author

Model-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib Development.

Clinical and translational science·2025
Same journal

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026
Same journal

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Clinical and translational science·2026
Same journal

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026
Same journal

Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants.

Clinical and translational science·2026
Same journal

Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer.

Clinical and translational science·2026
Same journal

EPHX2 Orchestrates Intestinal Epithelial Barrier Repair in Ulcerative Colitis: An Integrated Multi-Omics and Experimental Study.

Clinical and translational science·2026
查看所有相关文章

相关实验视频

Updated: Jun 9, 2025

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.7K

SHAP分析的实用指南:解释监督机器学习模型在药物开发中的预测.

Ana Victoria Ponce-Bobadilla1, Vanessa Schmitt1, Corinna S Maier1

  • 1AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.

Clinical and translational science
|October 28, 2024
PubMed
概括
此摘要是机器生成的。

本指南解释了SHapley添加式解释 (SHAP) 用于解释药物开发中的人工智能 (AI) 和机器学习 (ML) 模型. SHAP提高了模型的透明度和可信度,以改善临床决策.

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K

相关实验视频

Last Updated: Jun 9, 2025

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.7K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K

科学领域:

  • 计算化学是一种计算化学.
  • 药理学 药理学是指药理学的学科.
  • 数据科学是数据科学.

背景情况:

  • 人工智能 (AI) 和机器学习 (ML) 越来越多地用于药物开发.
  • 解释复杂的AI/ML模型预测仍然是一个重大挑战,阻碍了临床采用.
  • 在AI/ML模型中缺乏透明度限制了信任和有效的决策.

研究的目的:

  • 为解释AI/ML模型提供SHapley添加式解释 (SHAP) 的实用指南.
  • 提高AI/ML模型在药物开发中的透明度和可信度.
  • 为了促进AI/ML预测的更深入的理解和临床应用.

主要方法:

  • 专注于SHAP,一种基于特征的可解释性方法,用于监督的ML模型.
  • 教程涵盖了对回归和分类问题的应用.
  • 在标准ML黑盒子和内在可解释模型上演示SHAP分析.

主要成果:

  • 概述SHAP可视化图谱及其解释.
  • 讨论用于SHAP实施的可用软件.
  • 突出了对二进制终点和时间序列模型的最佳实践和考虑.

结论:

  • SHAP分析为解释药物开发中的AI/ML模型提供了一种实用方法.
  • 通过SHAP增强模型解释性可以改善临床决策.
  • 目前正在进行的进展旨在解决SHAP目前的局限性.